Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 3/20 | 0.51 |
| ▸ | HTR2B | P41595 | 5/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.37 |
| ▸ | HTR1F | P30939 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | PLG | P00747 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL196337 | 0.82 | — | — | |
| SCHEMBL7983041 | 0.81 | HTR2B (0.45) | ADRA1AHTR2BJAK1F10 | |
| SCHEMBL7996883 | 0.81 | HTR2B (0.45) | ADRA1AHTR2BADRA2AADRA1DADRA1B | |
| SCHEMBL9761882 | 0.80 | MAP4K4 (0.46) | ADRA1AHTR2BADRA2AADRA1DADRA1B | |
| SCHEMBL14450364 | 0.79 | HTR2B (0.41) | ADRA1AHTR2BJAK1 | |
| SCHEMBL7809418 | 0.79 | ADRA1A (0.52) | ADRA1AHTR2BADRA2AADRA1DADRA1B | |
| SCHEMBL4585762 | 0.79 | ADRA1A (0.52) | ADRA1AHTR2BADRA2AADRA1DADRA1B | |
| SCHEMBL14334197 | 0.78 | HTR2B (0.45) | ADRA1AHTR2BF10 | |
| SCHEMBL1494449 | 0.78 | — | — | |
| SCHEMBL184451 | 0.78 | ADRA1A (0.55) | ADRA1AHTR2BADRA2AADRA1DADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961225-B2 | Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-03-30 | — | — | US | disclosed |
| US-20200325118-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | NXERA PHARMA UK LIMITED (GB) | 2020-10-15 | — | — | US | disclosed |
| US-10689368-B2 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-06-23 | — | — | US | disclosed |
| US-10385039-B2 | Bicyclic aza compounds as muscarnic M1 receptor and/or M4 receptor antagonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-08-20 | — | — | US | disclosed |
| US-10196380-B2 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-02-05 | — | — | US | disclosed |
| US-20180179184-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-06-28 | — | — | US | disclosed |
| US-20180179184-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2018-06-28 | — | — | US | disclosed |
| EP-3102568-B1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS. | HEPTARES THERAPEUTICS LTD (GB) | 2018-06-27 | — | — | EP | disclosed |
| US-9926297-B2 | Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-03-27 | — | — | US | disclosed |
| US-9926297-B2 | Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-03-27 | — | — | US | disclosed |
| US-20160000785-A1 | Novel Imidazole Amines as Modulators of Kinase Activity | MERCK PATENT GMBH (DE) | 2016-01-07 | — | — | US | disclosed |
| US-9145392-B2 | Imidazole amines as modulators of kinase activity | MERCK PATENT GMBH (DE) | 2015-09-29 | — | — | US | disclosed |
| WO-2015118342-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AGONISTS. | HEPTARES THERAPEUTICS LIMITED (GB) | 2015-08-13 | — | — | WO | disclosed |
| US-20140343029-A1 | Novel Imidazole Amines as Modulators of Kinase Activity | MERCK PATENT GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
| EP-1812445-A1 | PHARMACEUTICAL COMPOUNDS | Piramed Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006046031-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
| WO-2005032551-A1 | TREATMENT OF CARDIOVASCULAR DISEASE WITH INHIBITORS OF p38 KINASE | SCIOS INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| WO-2004024083-A2 | METHODS OF BONE HEALING | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2004-03-25 | — | — | WO | disclosed |
| US-5071855-A | Antihistamines, antiallergens | DOMPE FARMACEUTICI SPA (IT) | 1991-12-10 | — | — | US | disclosed |
| EP-0397614-A2 | Pharmacologically active piperdinylimidazopyridines | DOMPE' FARMACEUTICI S.p.A. (IT) | 1990-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160000785-A1 | Novel Imidazole Amines as Modulators of Kinase Activity | MAP3K11, MAP3K20, MAP3K19 | ADRA1A 861/4885HTR2B 2918/4885ADRA2A 981/4885 |
| US-20200325118-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR | CHRM1, CHRM2, CHRM4 | ADRA1A 32/4885HTR2B 1181/4885ADRA2A 65/4885 |
| US-10196380-B2 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonists | CHRM1, CHRM2, CHRM4 | ADRA1A 31/4885HTR2B 1362/4885ADRA2A 62/4885 |
| US-20140343029-A1 | Novel Imidazole Amines as Modulators of Kinase Activity | MAP3K11, MAP3K20, MAP3K19 | ADRA1A 861/4885HTR2B 2918/4885ADRA2A 981/4885 |
| US-10961225-B2 | Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor | CHRM1, CHRM2, CHRM4 | ADRA1A 32/4885HTR2B 1181/4885ADRA2A 65/4885 |
| US-10689368-B2 | Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor | CHRM1, CHRM2, CHRM4 | ADRA1A 32/4885HTR2B 1181/4885ADRA2A 65/4885 |
| US-10385039-B2 | Bicyclic aza compounds as muscarnic M1 receptor and/or M4 receptor antagonists | CHRM1, CHRM2, CHRM5 | ADRA1A 53/4885HTR2B 956/4885ADRA2A 104/4885 |
| US-20180179184-A1 | BICYCLIC AZA COMPOUNDS AS MUSCARINIC M1 RECEPTOR AND/OR M4 RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM4 | ADRA1A 31/4885HTR2B 1362/4885ADRA2A 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.